Saturday, July 3, 2010

Global scenario of microbes, infections, antibiotics and resistance - By Dr. A.J. Tamhankar

-New antibiotics-AntibaBoldcterial NXL103 (flopristin/linopristin) starts Phase II clinical trial--- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces that its most advanced oral antibacterial NXL103 (flopristin/linopristin), has started a Phase II clinical trial in adults with acute bacterial skin and skin structure infections (ABSSSI). The trial is designed to assess the safety and efficacy of NXL103 in comparison to oral linezolid.
- Eschar With Cellulitis as a Clinical Predictor in Community-Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Skin Abscess -A central black eschar with cellulitis has good specificity and high positive predictive value in diagnosing CA-MRSA infection. (The Journal of Emergency Medicine, May 2010)
-'Hidden' tuberculosis raises drug-resistance fears ;New study doubles known rate of infection at a South African hospital.
-MRSA in Patients With Cystic Fibrosis Linked to Shorter Survival Time (CME)
-Extensive Drug Resistance found in Malaria and Tuberculosis
-Tackling antimicrobial resistance- WHO Patient Safety is working towards finding solutions how best to support ongoing international activities to address AMR. Activities are also ongoing to finalize an AMR work plan document during the first half of 2010.
-Bacterial Burden and Wound Outcomes as Influenced by Negative Pressure Wound Therapy
-Vancomycin Dosing: Guidance for Clinicians
-Infection Control Practices in Ambulatory Surgical Centers
-Contraceptive Use to stop infections: New Clinical Guidance From the CDC

No comments:

Read The ``TRUE LIFE STORY``of a family infected with MRSA